

Please type a plus sign (+) inside this box → ☐

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b> (to be used for all correspondence after initial filing)	<b>Application Number</b>	09/724,961	
	<b>Filing Date</b>	November 28, 2000	
	<b>First Named Inventor</b>	Schenk, Dale B.	
	<b>Group Art Unit</b>	1647	
	<b>Examiner Name</b>	Turner, Sharon	
<b>Total Number of Pages in This Submission</b>	11	<b>Attorney Docket Number</b>	15270J-004752US

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Response	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	1. Return Postcard (1 pg)
<input checked="" type="checkbox"/> Information Disclosure Statement (3 pp) w/attached PTO/SB/08A (1 pg) and PTO/SB/08B (5 pp) (w/o refs 220-304)	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s)	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application	<b>Remarks</b>	The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

<b>Firm and Individual name</b>	Townsend and Townsend and Crew LLP Rosemarie L. Celli	Reg. No. 42,397
<b>Signature</b>	<i>Rosemarie L. Celli</i>	
<b>Date</b>	<i>August 28, 2002</i>	

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service, Technical Center 1600, VIA HAND DELIVERY addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date: August 27, 2002

<b>Typed or printed name</b>	Heather Savia	<b>Date</b>	August 27, 2002
<b>Signature</b>	<i>Heather Savia</i>		

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. PA 3245650 v1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED  
TECH CENTER 1800/2900  
02 AUG 27 PM 2:06

In re application of:

Dale B. Schenk

Application No.: 09/724,961

Filed: November 28, 2000

For: PREVENTION AND TREATMENT  
OF AMYLOIDOGENIC DISEASE

Examiner: Turner, Sharon

Art Unit: 1647

SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT UNDER 37  
CFR §1.97 and §1.98

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

The references cited on attached PTO/SB/08A and PTO/SB/08B forms are being called to the attention of the Examiner. In accordance with 37 CFR §1.98(d), copies of the references can be found in Application No. 09/322,289, filed May 28, 1999 (Attorney Docket No. 15270J-004740US). It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

"Grant Application; Raso, Immunology of Alzheimer's Disease', 1/1998," cited by the Examiner in Application No. 09/579,690, is submitted herewith as cite no. 304. Application No. 09/579,690 is a commonly owned copending application directed to related subject matter. Applicant believes "1/1998" is not the publication date as alleged by the Examiner, but refers to the grant funding cycle. Applicant further believes the date of public accessibility, if any, is unknown. Applicant wishes to bring to the Examiner's attention that a copy of a grant application believed to have been submitted by Victor Raso for NIH Grant 1 R43 AGI 5746-01 on August 29, 1997 was previously submitted as cite no. 144. Cite no. 144 is a redacted version of cite no. 304. Applicant obtained cite no. 144 under the Freedom of Information Act (FOIA). It is believed that the grant proposal would not have been accessible

under FOIA before April 2, 1998, but the exact date of public accessibility, if any, is not known to Applicant.

The Assignee of the instant application is a licensee of U.S. Patent No. 5,688,651, which is directed in part to subject matter related to the instant application. U.S. Patent No. 5,688,651 is now undergoing examination reissue as Application No. 09/441,140. U.S. Application No. 09/441,140 is cited in the PTO/SB/08A form attached hereto. U.S. Patent No. 5,688,651 was cited in the IDS submitted September 20, 2001.

Applicant wishes to bring to the Examiner's attention that Application No. 09/723,762 filed 11/28/00, a commonly owned copending application directed to related subject matter, was previously cited in error by Applicant as Application No. 09/724,762.

Further, Applicant wishes to bring to the Examiner's attention that Application No. 09/724,570 filed 11/28/00, a commonly owned copending application directed to related subject matter, was previously cited as Application No. 09/724,569. Due to a PTO clerical error, this application and another separate, unrelated application were both assigned Application No. 09/724,569. The Office corrected this error by assigning Application No. 09/724,570 to the application previously cited as Application No. 09/724,569.

In addition to the commonly owned copending applications directed to related subject matter previously cited, Applicant wishes to bring the following applications to the Examiner's attention:

09/979,701 filed 03/13/01 (U.S. National Stage of PCT/US00/14810 filed 05/26/00);

09/979,952 filed 04/04/02 (U.S. National Stage of PCT/US00/15239 filed 06/01/00); and,

09/980,568 filed 03/12/02 (U.S. National Stage of PCT/US00/15302 filed 06/01/00).

Applicant also cites the following copending application directed to related subject matter but subject to different assignment:

10/010,942 filed 12/06/01.


Applicant also cites the following abandoned application directed to related subject matter but subject to different assignment:

60/251,892 filed 12/06/00.

As provided for by 37 CFR 1.97(g) and (h), no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information, and no inference should be made that the information and references cited are, or are considered to be material to patentability because they are in this statement. No inference should be made that the information and references cited are prior art merely because they are in this statement.

Applicant believes that no fee is required for submission of this statement, since it is being submitted prior to the first Office Action. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

  
Rosemarie L. Celli  
Reg. No. 42,397

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, 8<sup>th</sup> Floor  
San Francisco, California 94111-3834  
Tel: 650-326-2400  
Fax: 650-326-2422  
RLC